Sussex Drug Discovery Centre (SDDC)

Principal Investigators

 

 


 

Martin has devoted his research career to realising the therapeutic potential of ion channels in both industrial and academic settings. Subsequent to completing a BSc degree in Pharmacology at the University of Leeds, Martin received his PhD from the Department of Pharmaceutical Sciences at the University of Aston in Birmingham by studying ion channels in bone and muscle cells. His ion channel research continued throughout his post-doctoral studies at Imperial College and in 1998 Martin was appointed as lecturer in Vascular Physiology at Imperial College School of Medicine. Martin joined Novartis in 2001 in the Respiratory Diseases Area based in Horsham UK, and established an industry leading ion channel discovery group focused upon programs for the treatment of respiratory, CNS, inflammatory and cardiovascular diseases. Martin and his associated teams made pivotal contributions to the identification of numerous clinical candidates, several of which are still progressing through clinical development. In 2014 Martin joined the University of Sussex, establishing a group developing respiratory therapeutics programs and collaborating with colleagues in CNS ion channel drug discovery. Martin is also a co-founder and Chief Scientific Officer of Enterprise Therapeutics, a Sussex-based respiratory biotech company.